Association of the disease duration and administered therapy with metabolic syndrome in patients with systemic lupus erythematosus

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL
Jovana Cvetković, Sonja Stojanović, Ivan Tasić, Bojana Stamenković, Jovan Nedović, Sanja Stojanović
{"title":"Association of the disease duration and administered therapy with metabolic syndrome in patients with systemic lupus erythematosus","authors":"Jovana Cvetković, Sonja Stojanović, Ivan Tasić, Bojana Stamenković, Jovan Nedović, Sanja Stojanović","doi":"10.5937/afmnai40-40813","DOIUrl":null,"url":null,"abstract":"Aim. The aim of the paper was to examine the impact of disease duration and administered therapy on the development of metabolic syndrome (MetS) in patients with systemic lupus erythematosus (SLE). Material and methods. This study involved 55 patients (50 females and 5 males) with the diagnosis and 49 healthy controls of similar age. MetS was defined according to modified NCEP-ATP III diagnostic criteria, and obesity was defined by body mass index BMI > 30. Results. In the group of SLE patients with MetS, there were 23 individuals (41.82%). In the control group, there were 10 (20.4%) patients with MetS. There were significantly more SLE patients with MetS in comparison to the controls (p = 0.04). Duration of the disease in the group with MetS was longer in comparison to those without MetS, but it was not statistically significant (15.35 ± 10.26 vs 10.44 ± 7.88, p = 0.073). The study confirmed that there is a moderate association (CC = 0.355) between disease duration and number of MetS parameters, however, this dependency was not statistically significant (p = 0.439). In the group without MetS, there were statistically more patients treated with antimalarial drugs monotherapy (p = 0.023). It has been found that the patients with MetS were treated with corticosteroid therapy longer than those without MetS, but it was not statistically significant (153.57 ± 103.34 vs 114.75 ± 83.32, p = 0.129). Conclusion. Patients with longer SLE duration have more often MetS. It has been shown that, statistically, more patients without MetS were treated with antimalarial drugs monotherapy, and that long-term CS use, in our study, was not associated with higher incidence of MetS.","PeriodicalId":7132,"journal":{"name":"Acta Facultatis Medicae Naissensis","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Facultatis Medicae Naissensis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5937/afmnai40-40813","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Aim. The aim of the paper was to examine the impact of disease duration and administered therapy on the development of metabolic syndrome (MetS) in patients with systemic lupus erythematosus (SLE). Material and methods. This study involved 55 patients (50 females and 5 males) with the diagnosis and 49 healthy controls of similar age. MetS was defined according to modified NCEP-ATP III diagnostic criteria, and obesity was defined by body mass index BMI > 30. Results. In the group of SLE patients with MetS, there were 23 individuals (41.82%). In the control group, there were 10 (20.4%) patients with MetS. There were significantly more SLE patients with MetS in comparison to the controls (p = 0.04). Duration of the disease in the group with MetS was longer in comparison to those without MetS, but it was not statistically significant (15.35 ± 10.26 vs 10.44 ± 7.88, p = 0.073). The study confirmed that there is a moderate association (CC = 0.355) between disease duration and number of MetS parameters, however, this dependency was not statistically significant (p = 0.439). In the group without MetS, there were statistically more patients treated with antimalarial drugs monotherapy (p = 0.023). It has been found that the patients with MetS were treated with corticosteroid therapy longer than those without MetS, but it was not statistically significant (153.57 ± 103.34 vs 114.75 ± 83.32, p = 0.129). Conclusion. Patients with longer SLE duration have more often MetS. It has been shown that, statistically, more patients without MetS were treated with antimalarial drugs monotherapy, and that long-term CS use, in our study, was not associated with higher incidence of MetS.
系统性红斑狼疮患者代谢综合征的疾病持续时间和给药治疗的相关性
的目标。本文的目的是研究疾病持续时间和给药治疗对系统性红斑狼疮(SLE)患者代谢综合征(MetS)发展的影响。材料和方法。本研究纳入55例确诊患者(50例女性,5例男性)和49例年龄相仿的健康对照。根据修改后的NCEP-ATP III诊断标准定义MetS,根据体重指数BMI >定义肥胖;30.结果。合并MetS的SLE患者组有23例(41.82%)。在对照组中,有10例(20.4%)患者发生MetS。与对照组相比,合并met的SLE患者明显更多(p = 0.04)。有MetS组病程较无MetS组长,但差异无统计学意义(15.35±10.26 vs 10.44±7.88,p = 0.073)。研究证实,病程与MetS参数数量之间存在中度相关性(CC = 0.355),但这种相关性无统计学意义(p = 0.439)。在没有MetS的组中,使用抗疟药物单一治疗的患者有统计学意义(p = 0.023)。研究发现,有MetS的患者比无MetS的患者接受皮质类固醇治疗的时间更长,但差异无统计学意义(153.57±103.34 vs 114.75±83.32,p = 0.129)。结论。SLE病程较长的患者有较多的MetS。从统计上看,更多未患MetS的患者接受抗疟药物单药治疗,而在我们的研究中,长期使用抗疟药物与较高的MetS发生率无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Facultatis Medicae Naissensis
Acta Facultatis Medicae Naissensis MEDICINE, GENERAL & INTERNAL-
CiteScore
0.70
自引率
0.00%
发文量
13
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信